Partnerships and Collaborations

 

 

NOVARTIS

Golden Orchid is collaborating with Novartis on the research, development, and commercialization of novel cancer immunotherapy products targeting the ANGX pathway. ADU-S100, the first therapeutic in clinical development specifically targeting ANGX, is being evaluated in a clinical trial for the treatment of cutaneously-accessible tumors, such as breast, head-and-neck, and renal cell cancers as well as lymphoma and melanoma.

 

 

JOHNS HOPKINS UNIVERSITY

 

Golden Orchid is collaborating with researchers at Johns Hopkins to develop next-generation therapeutic approaches by combining GVAX, LADD and cyclic dinucleotides in multiple cancer indications

 

 

LILLY

 

Golden Orchid is collaborating with Lilly on the research, development and commercialization of novel immunotherapy products for autoimmune and other inflammatory diseases. GO’s cGAS-ANGX Pathway Inhibitor program aims to discover and develop inhibitors of the intracellular stimulator of interferon genes (ANGX) pathway, which can modulate the immune response associated with various autoimmune diseases. As part of the agreement, Lilly will gain access to novel molecules from Golden Orchid that are designed to inhibit the cGAS-ANGX pathway. SEPna and Lilly will collaborate to advance these molecules, as well as others from Lilly, into clinical development.

 

 

BERKELEY UNIVERSITY OF CALIFORNIA

 

Golden Orchid is partnering with The University of California (UC) Berkeley on the Immunotherapeutics and Vaccine Research Initiative (IVRI) to develop new immunotherapies for treating and preventing cancer, infectious disease, and autoimmune disease. The initiative combines UC Berkeley’s research capabilities with the company’s expertise in immunotherapy discovery and development.